Literature DB >> 28504917

Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment.

Julien Lalut1, Delphine Karila1, Patrick Dallemagne1, Christophe Rochais1.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia affecting millions of patients worldwide which can only be treated with symptomatic drugs. Among the numbers of biological targets which are today explored in order to prevent or limit the progression of AD, the modulation of 5-HT6R and 5-HT4R appeared to be promising. This modulation has been proved to enhance the cognition in AD through modulation of the neurotransmitter system but could also be beneficial in order to limit the amyloid pathology. This review will describe recent advances in the understanding of this modulation as well as the medicinal chemistry of 5-HT6R or 5-HT4R ligands from synthesis to ongoing clinical trials.

Entities:  

Keywords:  5-HT4 receptors; 5-HT6 receptors; Alzheimer’s disease; multitarget-directed ligand; neurodegenerative disease

Mesh：

Substances：

Year:  2017        PMID： 28504917     DOI： 10.4155/fmc-2017-0031

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


  10 in total

1.  Serotonin signaling by maternal neurons upon stress ensures progeny survival.

Authors:  Srijit Das; Felicia K Ooi; Johnny Cruz Corchado; Leah C Fuller; Joshua A Weiner; Veena Prahlad
Journal:  Elife       Date:  2020-04-23       Impact factor: 8.140

2.  First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.

Authors:  Ramakrishna Nirogi; Gopinadh Bhyrapuneni; Nageswara Rao Muddana; Vinod Kumar Goyal; Santosh Kumar Pandey; Abdul Rasheed Mohammed; Jyothsna Ravula; Satish Jetta; Veera Raghava Chowdary Palacharla
Journal:  Clin Drug Investig       Date:  2021-03-31       Impact factor: 2.859

Review 3.  Central nervous system effects of 5-HT7 receptors: a potential target for neurodegenerative diseases.

Authors:  Alejandro Quintero-Villegas; Sergio Iván Valdés-Ferrer
Journal:  Mol Med       Date:  2022-06-20       Impact factor: 6.376

4.  Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.

Authors:  Ramakrishna Nirogi; John Ieni; Vinod Kumar Goyal; Jyothsna Ravula; Satish Jetta; Anil Shinde; Pradeep Jayarajan; Vijay Benade; Veera Raghava Chowdary Palacharla; Dhanunjay Kumar Dogiparti; Venkat Jasti; Alireza Atri; Jeffrey Cummings
Journal:  Alzheimers Dement (N Y)       Date:  2022-06-01

5.  Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer's Disease Treatment through Rigidification Strategy.

Authors:  Cédric Lecoutey; Rémi Legay; Audrey Davis; Jana Sopková-de Oliveira Santos; Patrick Dallemagne; Christophe Rochais
Journal:  Molecules       Date:  2021-04-26       Impact factor: 4.411

Review 6.  Memory Disorders Related to Hippocampal Function: The Interest of 5-HT4Rs Targeting.

Authors:  Candice M Roux; Marianne Leger; Thomas Freret
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

Review 7.  Exogenous Bioactive Peptides Have a Potential Therapeutic Role in Delaying Aging in Rodent Models.

Authors:  Jianqiang Wang; Yixin Wu; Zhongxu Chen; Yajuan Chen; Qinlu Lin; Ying Liang
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 8.  The serotonergic system dysfunction in diabetes mellitus.

Authors:  Yan Cai; Xiaolong Li; Hongli Zhou; Jiyin Zhou
Journal:  Front Cell Neurosci       Date:  2022-07-14       Impact factor: 6.147

Review 9.  Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty.

Authors:  Nurul Husna Ibrahim; Mohamad Fairuz Yahaya; Wael Mohamed; Seong Lin Teoh; Chua Kien Hui; Jaya Kumar
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

Review 10.  From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.

Authors:  Jazmín Alarcón-Espósito; Michael Mallea; Julio Rodríguez-Lavado
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.